Analysis of interleukin-10 promoter single nucleotide polymorphisms and risk of non-Hodgkin lymphoma in a Malaysian population

Abstract

We evaluated the association of two IL10 single nucleotide polymorphisms (SNPs) (rs1800896 and rs1800871) with non-Hodgkin lymphoma (NHL) risk in the three major races of the Malaysian population (Malay, Chinese and Indian; 317 cases and 330 controls). Our initial screening demonstrated that rs1800871 but not rs1800896 was significantly associated with increased NHL risk in Malays (p_Malay-Rec = 0.007) and Chinese only (p_Chinese-Rec = 0.039). Subsequent combined analysis of the Malay and Chinese revealed significant association of rs1800871 with all (ALL) NHL subtypes (p_{Meta-ALL-NHL-Rec} = 0.001), ALL B-cell subtypes (p_{Meta-ALL-B-cell-Rec} = 0.003), diffuse large B-cell lymphoma (DLBCL) subtype (p_{Meta-DLBCL-Rec} = 0.002) and ALL T-cell subtypes (p_{Meta-ALL-T-cell-Rec} = 0.031). SNP rs1800896 showed increased risk only in follicular lymphoma (FL) (p_Meta-FL-Dom = 0.0004). We also detected a male-specific association of rs1800871 with increased NHL risk (p_{Meta-Male-ALL-NHL-Rec} = 0.006) in the combined analysis. To our knowledge, this is the first report on the association of IL10 promoter SNPs with NHL susceptibility in the three major races of Malaysia.

Keywords::

• NHL
• genetic susceptibility
• SNP
• IL10

Acknowledgements

The authors would like to thank the Director General of Health, Ministry of Health of Malaysia for permission to publish this article. The authors thank all the participants of the study, Khor Xue Fen and Ng Wai Yan for their assistance with genotyping, and staff of the blood bank, UMMC and Ampang Hospital. The work was supported by a grant from MOSTI eScience (12-02-03-2023) and a High Impact Research Grant UM-MOHE UM.C/625/1/HIR/MOHE/ CHAN-02 (H-50001-A000023) from the Ministry of Higher Education, Malaysia.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.